An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients.

Trial Profile

An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Nov 2017

At a glance

  • Drugs Moxifloxacin (Primary) ; Ofloxacin
  • Indications Bacterial infections; Infectious conjunctivitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Alcon
  • Most Recent Events

    • 30 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 04 Dec 2013 Planned number of patients changed from 434 to 1042 as reported by ClinicalTrials.gov.
    • 04 Dec 2013 Planned end date changed from 1 May 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top